Physician profile
William David Bruce
NPI 1194713560
$11,658.54
in general payments reported to CMS, 2019-2025
30 companies · $487 in 2025
The $487 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $79.26 · 2021: $2,645 · 2022: $420 · 2023: $794 · 2024: $5,457 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801 · Travel and Lodging: $2,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,800.55 |
| Travel and Lodging | $2,937.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trimed, INC. | $3,151.30 | 2024 | |
| Arthrex, INC. | $2,640.99 | 2019-2024 | |
| Alpha Orthopedic Systems | $2,504.66 | 2019-2021 | |
| Smoky Mountain Surgical LLC | $1,103.31 | 2024-2025 | |
| Zimvie INC. | $845.07 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $387.69 | 2019-2025 | Euflexxa |
| Linvatec Corporation | $219.87 | 2022-2025 | Allograft Tissue, Biobrace 23mm, Hall Power |
| Pacira Pharmaceuticals Incorporated | $109.18 | 2021-2025 | Zilretta, Iovera, Exparel |
| Abbott Laboratories | $103.98 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Atricure, INC. | $89.47 | 2024 | |
| Horizon Therapeutics Plc | $81.82 | 2019-2022 | |
| Smith+Nephew, INC. | $55.83 | 2020-2025 | Pico 14 |
| Pacira Therapeutics, INC. | $50.80 | 2020-2021 | |
| Globus Medical, INC. | $30.10 | 2021 | |
| Abbvie INC. | $29.18 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Djo, LLC | $28.31 | 2025 | Cmf |
| Curonix LLC | $23.71 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ultragenyx Pharmaceutical INC. | $21.07 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.97 | 2025 | Wainua |
| Novo Nordisk INC | $20.28 | 2021 | |
| Seqirus USA INC | $19.65 | 2022 | |
| Medtronic, INC. | $18.18 | 2024 | Kyphon Express II Kyphopak Tray |
| Amgen INC. | $17.21 | 2023 | Evenity, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.97 | 2025 | Caplyta |
| Vertex Pharmaceuticals Incorporated | $14.30 | 2025 | |
| Jazz Pharmaceuticals INC. | $13.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.29 | 2022 | |
| Fidia Pharma USA INC. | $11.91 | 2022 | |
| Ethicon US, LLC | $10.92 | 2019 | |
| Orthofix Medical, INC. | $8.48 | 2025 | Physio-Stim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.